© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
July 30, 2021
More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.
July 23, 2021
Although the new drug aducanumab has grabbed all the headlines, the future of Alzheimer treatment may be just as much about public health campaigns as it is about psychopharmacology. In this episode of Psych Pearls, we find out why.
July 14, 2021
Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?
July 08, 2021
Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.
June 28, 2021
How can volunteering to play video games help brain research?
June 25, 2021
Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.
June 16, 2021
The FDA approval of aducanumab has given hope to millions of patients with Alzheimer disease—but will it live up to the hype?
June 10, 2021
What effect will aducanumab have on Alzheimer disease treatment?
June 07, 2021
This one-of-a-kind Alzheimer disease treatment targets the amyloid beta plaques in the brain, potentially slowing cognitive decline.
May 29, 2021
Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.